NCT05390892 · Brigham and Women's Hospital
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
(PRECIDENTD)
What this study is about
PRECIDENTD is a randomly assigned, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD.
View original scientific description
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD.
Interventions
DRUG
SGLT2 inhibitor
Empagliflozin, dapagliflozin, or canagliflozin
DRUG
GLP-1 receptor agonist
Dulaglutide, liraglutide, semaglutide
Primary outcome measures
Total (first and recurrent) cardiovascular, kidney, and death events
Time frame: Through study completion, with an average follow up of approximately 3 years
total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Type 2 diabetes based on clinical diagnosis
- HbA1c ≥6% measured within 12 months prior to screening
- Secondary prevention cohort (at least 70% of cohort):
- Age 40 to 80 years
- Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following
- Coronary heart disease defined by at least one of the following: prior myocardial infarction, prior coronary percutaneous coronary intervention, ≥50% stenosis of a coronary artery documented by invasive or non-invasive imaging (including CT coronary angiography), positive stress test, or coronary artery calcium score \>400 Agatston units;
- Cerebrovascular disease defined by at least one of the following: prior ischemic stroke, prior carotid revascularization procedure, carotid stenosis ≥ 50% documented by X-ray angiography, MR angiography, CT angiography, or Doppler ultrasound;
- Symptomatic peripheral artery disease defined by at least one of the following: l
Where
- Huntsville, Alabama
- Scottsdale, Arizona
- Los Angeles, California
- Miami, Florida
- Pembroke Pines, Florida
- Johns Creek, Georgia
- Suwanee, Georgia
- Chicago, Illinois
- Hinsdale, Illinois
- Iowa City, Iowa
- Fairway, Kansas
- Baltimore, Maryland
And 22 more locations — see the full list below.
Collaborators
Patient-Centered Outcomes Research Institute
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Apr 13, 2026 · Source of record for eligibility and locations